<?xml version="1.0" encoding="UTF-8"?>
<p id="para160">Access to convalescent serum samples is important to establish whether neutralising antibodies are present and to develop potential antigens for vaccine development. The first broad category of enabling technologies include rapid antibody development platforms for therapeutic or prophylaxis candidates and assay reagents.
 <xref rid="bib18" ref-type="bibr">
  <sup>18</sup>
 </xref> Presently, the time taken to translate manufactured antibodies from discovery through to the clinic remains a hurdle to the broad applicability of this therapeutic. Improving speed or decreasing cost of goods can enable these platforms to be routinely used in the context of epidemic response.
</p>
